[Dosage of inactivated influenza vaccine for infants]

Daisuke Tamura1, Takuma Miura, Ritei Uehara

  • 1Department of Pediatrics, Jichi Medical School.

Insights

Infants under one year old showed lower protective antibody responses to inactivated influenza vaccines compared to older children. Increasing the vaccine dosage for infants is recommended to achieve protective antibody levels.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Immunology

Context:

  • The standard inactivated influenza vaccine dosage for infants under one year old in Japan is 0.1 mL.
  • This dosage is half that administered in Europe and the USA.
  • Lower vaccine efficacy in infants may be linked to the reduced dosage.

Purpose:

  • To investigate the hypothesis that a lower dosage of inactivated influenza vaccine contributes to reduced efficacy in infants under one year old.
  • To compare the immunogenicity of inactivated influenza vaccine in infants (8-11 months) versus older children (12-16 months).

Summary:

  • A prospective study compared antibody titers after two doses of inactivated influenza vaccine in two age groups: infants (0.1 mL dose) and children over one year (0.2 mL dose).
  • Infants demonstrated significantly lower proportions of protective hemagglutinin inhibiting antibody titers and fewer four-fold increases in antibodies across all tested strains (A/H1N1, A/H3N2, B) compared to older children.
  • Mean antibody titers were also significantly lower in infants than in the older children's group.

Impact:

  • Findings suggest that the lower inactivated influenza vaccine dosage in infants is associated with diminished antibody responses.
  • Results support the need for adequate vaccine dosage to achieve protective antibody levels in infants.
  • This research could inform revised vaccination guidelines for infants to improve influenza protection.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
Vaccinations01:51

Vaccinations

Overview
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...